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Clopidogrel Enhances Periodontal Repair in Rats Through Decreased 
Inflammation 
Abstract 
Aim 
We hypothesized that platelet inactivation induced by drugs might interfere with periodontal repair in 
experimental periodontitis by suppressing the release of biological mediators from platelets at the site of 
injury. 
Material and Methods 
60 rats were randomly assigned to 6 groups (n=10) and ligatures were placed around lower first molars of 
three groups. The other three groups were used as negative controls. Ligatures were removed after 10 
days of periodontitis induction and all groups were submitted to treatment with aspirin (Asp) (30 mg/kg), 
clopidogrel (Clop) (75 mg/kg) or NaCl 0.9% intragastrically once daily for 3 days. Periodontal tissue was 
assessed by the measurement of CXCL12, CXCL4, CCL5 and PDGF by ELISA; histomorphometric analysis 
of PMN infiltration, attachment loss, bone loss and osteoclast numbers and quantification of blood 
vessels by imunnohistochemistry. 
Results 
During periodontal repair and treatment with NaCl 0.9%, CCL5 was decreased and CXCL12 increased 
when compared to negative control groups. Asp and Clop did not affect CCL5 expression, decreased 
CXCL12 but only Clop decreased CXCL4 and PDGF content compared to saline-treated animals. Clop 
increased blood vessel number, reduced PMN count, and decreased attachment and bone loss, also 
decreased osteoclast number in animals submitted or not to periodontal repair. 
Conclusion 
Systemic administration of Clop during 3 days improved the repair process associated with experimental 
periodontal disease, suggesting that it may have therapeutic value under situations where tissues 
undergo a transition from inflammation to repair. 
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Abstract
Aim—We hypothesized that platelet inactivation induced by drugs might interfere with
periodontal repair in experimental periodontitis by suppressing the release of biological mediators
from platelets at the site of injury.
Material and Methods—60 rats were randomly assigned to 6 groups (n=10) and ligatures were
placed around lower first molars of three groups. The other three groups were used as negative
controls. Ligatures were removed after 10 days of periodontitis induction and all groups were
submitted to treatment with aspirin (Asp) (30 mg/kg), clopidogrel (Clop) (75 mg/kg) or NaCl
0.9% intragastrically once daily for 3 days. Periodontal tissue was assessed by the measurement of
CXCL12, CXCL4, CCL5 and PDGF by ELISA; histomorphometric analysis of PMN infiltration,
attachment loss, bone loss and osteoclast numbers and quantification of blood vessels by
imunnohistochemistry.
Results—During periodontal repair and treatment with NaCl 0.9%, CCL5 was decreased and
CXCL12 increased when compared to negative control groups. Asp and Clop did not affect CCL5
expression, decreased CXCL12 but only Clop decreased CXCL4 and PDGF content compared to
saline-treated animals. Clop increased blood vessel number, reduced PMN count, and decreased
attachment and bone loss, also decreased osteoclast number in animals submitted or not to
periodontal repair.
Conclusion—Systemic administration of Clop during 3 days improved the repair process
associated with experimental periodontal disease, suggesting that it may have therapeutic value
under situations where tissues undergo a transition from inflammation to repair.
Keywords
clopidogrel; periodontal repair; inflammation; innate immunity; chemokines
Author for correspondence: Luis C. Spolidorio, Dept. of Physiology and Pathology, Faculdade de Odontologia de Araraquara,
UNESP-Univ Estadual Paulista, Rua Humaitá 1680, Araraquara, São Paulo, Brazil, Telephone / fax: +55 (0)16 33016479/+55 (0)16
33016488, lcs@foar.unesp.br.
Conflict of interest The authors declare that they have no conflict of interests.
NIH Public Access
Author Manuscript
J Clin Periodontol. Author manuscript; available in PMC 2015 March 01.
Published in final edited form as:
J Clin Periodontol. 2014 March ; 41(3): 295–302. doi:10.1111/jcpe.12203.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
INTRODUCTION
Platelet degranulation releases a plethora of biological mediators, such as chemokines,
cytokines and growth factors, such as platelet derived growth factor (PDGF), that have a
role in the inflammatory process and tissue regeneration. An alteration in the amount and
function of platelets affects thrombotic and inflammatory events that contribute to
cardiovascular diseases such as atherosclerosis (von Hundelshausen et al, 2007). C-X-C
motif ligand 4 (CXCL4 or Platelet Factor 4), C-X-C motif chemokine 12 (CXCL12) and C-
C motif ligand 5 (CCL5 or Regulated on Activation, Normal T cell Expressed and Secreted -
RANTES) are platelet chemokines released upon activation. CXCL12 is chemotactic for
lymphocytes. CXCL4, also known as platelet factor 4 promotes blood coagulation and is
chemotactic for neutrophils and fibroblasts, while CCL5 is chemotactic for T cells and plays
an active role in recruiting leukocytes into inflammatory sites. They act in the onset of tissue
repair and establish a pro-inflammatory environment that culminates in the recruitment and
activation of a variety of immune cells (Flad & Brandt, 2010).
In the context of periodontal regeneration, we have previously demonstrated that a
pronounced reduction of circulating platelets (thrombocytopenia) leads to a delay in
periodontal healing which is associated, at least in part, with decreased serum concentrations
of platelet-derived VEGF and endostatin (Spolidorio et al, 2010). Furthermore, platelet
inactivation by systemic administration of aspirin and clopidogrel attenuates the amount of
destruction that occurs with periodontitis by reducing the concentration of the inflammatory
mediators Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-alpha) and
Thromboxane A2 (TXA2); reducing the inflammatory infiltrate and increasing the amount of
collagen fibers (Coimbra et al, 2011). Moreover, platelet rich plasma (PRP) has been shown
to enhance regenerative treatment (Lekovic et al, 2012; Suaid et al, 2012; Dominiak et al,
2012).
Antiplatelet treatments include aspirin and thienopyridines (such as clopidogrel and
dipyridamole), abciximab or eptifibatide (Schomig et al, 1997; Bennett, 2001). Aspirin
irreversibly inactivates cyclooxygenase-1 (COX-1) activity and subsequent synthesis of
TXA-2. It also modifies the COX-2 enzymatic activity, induces lipoxin production that
facilitates the resolution of inflammation and inhibits prostanoid production that is generally
pro-inflammatory (Warner & Mitchell, 2002). Clopidogrel acts by irreversible antagonism
of platelet P2Y12 receptors expressed in the platelet membrane by inhibiting binding of the
endogenous ligand, adenosine diphosphate (ADP) (Bennett, 2001; Gao et al, 2009).
Because platelets contain an array of cytokines and growth factors they modulate
inflammatory and repair processes. In this study, we evaluated the effects of aspirin and
clopidogrel, the two most frequently prescribed antiplatelet drugs, on the transition from
periodontal inflammation to periodontal repair by the measurement of growth factors and
chemokines that acts in the onset of tissue repair CXCL12, CXCL4, CCL5 and PDGF,
histomorphometric analysis of PMN infiltration, attachment loss, bone loss and osteoclast
numbers and quantification of blood vessels by imunnohistochemistry.
MATERIAL AND METHODS
Animals
Sixty male adult Holtzman rats (Rattus norvergicus albinus) weighing 250-300 g were
housed under similar conditions in cages with access to food and water ad libitum. During
the whole experimental protocol, the rats were kept in a quiet room with controlled
temperature (22±1°C), humidity (65-75%) and a 12-h light-dark cycle. All experimental
protocols were approved by the local Ethics Committee for Animal Experimentation and
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performed in accordance with the guidelines of the Brazilian College for Animal
Experimentation (COBEA).
Chemicals
All drugs and reagents were purchased from Sigma Aldrich (Brazil), unless otherwise stated.
Ketamine and xylazine chloride (Francotar® and Virbaxil® respectively, both from Virbac
do Brasil Ind. Com. Ltda, São Paulo, SP, Brazil) were used for dissociative anesthesia of the
animals.
Evaluation of antiplatelet drug treatment on periodontal repair
Rats were randomly distributed into 6 groups (10 animals/group) as follows: vehicle-treated:
‘NaCl’, Aspirin-treated: ‘Asp’, Clopidogrel-treated: ‘Clop’, Repair (Rep)+vehicle-treated:
‘Rep+NaCl’, Repair+Aspirin-treated: ‘Rep+Asp’, Repair+Clopidogrel-treated: ‘Rep+Clop’.
The animals in the groups subjected to experimental periodontal repair were anesthetized
with 1 mg/kg body weight of ketamine and 0.4 mL/kg of xylazine for the induction of
experimental periodontal disease by the insertion of a 3.0 cotton ligature in a submarginal
position on the lower right and left first molars of each rat, as previously described
(Holzhausen et al, 2002). After 10 days, ligatures were removed to allow the spontaneous
repair of periodontal tissues over the subsequent 3 days. During these three days, animals
were treated with intragastrical daily doses of aspirin (Asp; 30 mg/kg) or clopidogrel (Clop;
75 mg/kg). Control rats were treated with the same volume of vehicle (NaCl 0.9%). These
doses have been previously shown to cause effective inhibition of platelet aggregation and
thrombus formation in rats (Coimbra et al, 2011; Ma et al, 2001; Sasaki et al, 1996; Taka et
al, 1999; Wallace et al, 1995). The animals from the other three groups were used as
negative controls, had no ligature-induced periodontitis and were treated with Asp, Clop and
NaCl 0.9% as described above.
Harvesting and processing of samples
At the end of the 13-day experimental period, animals were killed by anesthesia overdose
and the mandibles were carefully removed and dissected. Gingivo-mucosal tissues from the
right mandibular first molar of all animals were removed and total proteins extracted from
gingival tissue samples using a detergent-based extraction buffer (T-PER, Tissue Protein
Extraction Reagent; Pierce Biotechnology) containing a protease inhibitor cocktail (Protein
Stabilizing Cocktail; Santa Cruz Biotechnology) according to manufacturer’s instructions
(Pierce Biotechnology). The proteins were quantified using Lowry method (DC assay, Bio-
Rad Laboratories) and used for the analysis of PDGF, CXCL12, CCL5 and CXCL4 contents
by enzyme-linked immunosorbent assay (ELISA) from Life Technologies (Carlsbad, CA,
USA), according to the manufacturer’s instructions.
Histomorphometric analysis
Subsequently, left hemi-mandibles were fixed in 4% paraformaldehyde at 4°C for 48h and
decalcified in 4.13% EDTA solution (pH 7.2) at room temperature for approximately 3
months. Serial paraffin sections 5 μm thick were obtained from buccal–lingual aspects of the
whole left first molars and the samples of 5 animals subsequently stained with hematoxylin
and eosin (H&E) for histological/histometric evaluation. Bone loss was measured as the
distance between the cemento-enamel-junction (CEJ) and the highest peak from the top of
the alveolar bone crest (ABC). Attachment loss was measured by the distance between the
CEJ and the most coronal extent of connective tissue attachment to cementum and the the
bone area per total area (percent bone) by measuring the amount of bone in an area bounded
occlusally by the cemento-enamel junction to a distance 1mm apical and by the root surfaces
on the mesial and distal. This space included the gingiva, periodontal ligament and alveolar
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bone. Bone loss is represented by the relative decrease on the area occupied by bone, as
described in Liu et al, 2006. The number of polymorphonuclear (PMNs) leukocytes was
counted in the connective tissue 0.5 mm above the CEJ. 5 randomly chosen sections of each
animal in the total of 5 animals per group were examined at 200X magnification. A blinded
examiner who did not know the group to which an animal belonged analyzed all data.
Immunohistochemistry to identify osteoclasts and blood vessels
The sections from the other 5 animals were used to immunohistochemistry. An anti-tartrate-
resistant acid phosphatase primary antibody (Santa Cruz Biotechnology, 1:100) was used to
identify multinucleated osteoclasts adjacent to bone. In separate sections an antibody
specific for Factor VIII (Abcam, Cambridge, MA) diluted 1:100 was used to identify blood
vessels. Primary antibody was localized by a biotinylated secondary antibody followed by
avidin-biotin complex staining (Burlingame, CA, USA). For blood vessels tyramide signal
amplification was used to enhance the chromogenic signal (PerkinElmer, Waltham, MA,
USA). The number of TRAP+ cells was counted as the multinucleated cells adjacent from
the alveolar bone crest to an apical distance 1 mm below the CEJ and expressed as the
number per mm bone length. Blood vessels were counted in the connective tissue between
the CEJ-ABC. For both analyses, 5 sections were examined in 5 randomly selected fields at
600X magnification.
Statistical analysis
All data were expressed as mean ± SD. Differences among the groups were analyzed by
pairwise comparisons (Student t-test). P values less than 5% were considered statistically
significant.
RESULTS
All animals were alive at the end of the experimental period (13 days), and the recorded
body weights were 283.7±1.8, 292.0±2.1, 275.0±1.5, 258.0±4.1, 261.0±2.3 and 277.0±2.6 g
for NaCl, Asp, Clop, Rep+NaCl, Rep+Asp and Rep+Clop groups, respectively, without
significant difference. Neither occult bleeding nor hematoma after gingival intervention was
observed.
ELISA analysis
After induction of periodontitis and repair there was no difference in CXCL4 levels
compared to negative control groups. However, treatment with Clop significantly reduced
the expression of CXCL4 by 60% to 70% with (P<0.001) or without (P<0.001) the induction
of periodontitis. Asp induced a 50% decrease (P<0.0001) only after the induction of
periodontitis and repair (Figure 1B).
The gingival level of CCL5 was significantly decreased by 80% (P<0.0001) and CXCL12
increased by 75% (p<0.0001) in rats subjected to the induction of periodontitis and repair
compared to negative controls. During repair phase, treatment with Asp induced a 28% and
Clop a 37% decrease (P<0.001) in CXCL12 expression compared with the saline-treated
animals (Figure 1A and C) and did not affect CCL5 expression.
PDGF-AB expression was stimulated approximately 10 fold by induction of periodontitis
and repair (P<0.001) compared to negative control groups. During periodontal repair,
treatment with Clop but not Asp had a 75% reduction in PDGF-AB expression compared to
saline-treated animals (Figure 2).
Coimbra et al. Page 4
J Clin Periodontol. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
HISTOMORPHOMETRIC analysis
To evaluate the role of antiplatelet drugs on the repair process, ligatures were removed after
10 days in the animals of three experimental groups and they were submitted to treatments
with Asp, Clop and vehicle as described above.
Administration of Clop during the period of repair appears to have reduced inflammation
and improved the healing process. Clop-treated animals showed a reduced cellularity
(polymorphonuclear leukocytes (PMN) infiltrate by 62% (P <0.001), reduced attachment
loss by 45% (P <0.001) and reduced loss of periodontal bone height (CEJ-ABC distance) by
25% (P <0.001); therefore an augmented bone percentage when compared to saline-treated
animals (Figure 3 and 4 A, B, C and D).
Osteoclast numbers
To establish how antiplatelet therapy may affect bone resorption osteoclast numbers were
measured. The number of osteoclasts per millimeter of bone length was increased 3 fold by
induction of periodontitis and repair. Treatment of the experimental animals with Clop
completely blocked this increase (P<0.0001) and also decreased levels of osteoclasts
(P<0.001) in negative control group. In contrast Asp had no effect (P>0.05) (Figure 5 and
6).
Blood Vessels
Treatment with Clop during periodontal repair increased the number of blood vessels by
20% (p<0.0001) while Asp had no effect (P>0.05) compared to saline treated experimental
animals (Figure 7).
DISCUSSION
In our experimental model, removal of the disease-causing stimulus (ligature) initiates a
process that involves resolution of inflammation and a transition to repair. During the
proliferative phase of repair, a plethora of cells undergo dynamic phenotypic alterations that
can activate the inflammasome secreting cytokines and chemokines directly involved in the
inflammatory process. Some conditions such as diabetes, impairs the resolution of
inflammation and may affect the transition to repair. According to Pacios et al (2012)
diabetes prolongs inflammation and osteoclastogenesis in periodontitis and limits the normal
reparative process by negatively modulating factors that regulate bone. On the other hand,
Wada et al (2013) showed that a bone graft treatment with sustained release of salicylic acid
enhances bone regeneration in diabetic rats and accelerates bone regeneration in
normoglycemic animals.
In the context of periodontal repair, previously we have shown a net effect of inflammation
for regeneration after 15 days, without differences between the antiinflammatory effect of
aspirin and clopidogrel (Coimbra, 2011). In the early transition phase analysed in the present
study, there is an increased CXCL4, CXCL12, PDGF and higher levels of PMN infiltration
and osteoclasts compared to negative control animals that did not have periodontitis.
Administration of clopidogrel significantly decreased levels of chemokines CXCL4 and
CXCL12, PMN infiltration and osteoclast numbers suggesting that clopidogrel substantially
reduced the level of inflammation during the transition phase. This decrease in inflammation
is thought to be important in subsequent steps that involve repair. This is supported by an
increase in the number of blood vessels observed with clopidogrel and a decrease in the loss
of connective tissue attachment. Administration of aspirin had similar, but less marked
effects on the production of platelet-derived chemokines and production of PDGF was
barely attenuated. Also, aspirin did not attenuate loss of connective attachment and bone
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resorption. The latter is supported by the lack of effect on osteoclast numbers in the animals
treated with aspirin. Interestingly, administration of aspirin was not as effective as
clopidogrel in reducing inflammation as noted by a reduced effect on PMN infiltration or
osteoclast numbers and was less effective in promoting the transition to repair as noted by
relatively little effect on the number of blood vessels or connective tissue attachment levels.
The mechanisms by which clopidogrel improves the transition from inflammation to repair
has not yet been fully elucidated. Our data suggests that modulation of the disease-
associated inflammatory process in this early/transition phase is part of the mechanism. The
differences between the results of clopidogrel- and aspirin-treated animals may reflect
different biological mechanisms and potencies of these drugs. Clopidogrel is a
thyenopiridine that acts by irreversibly binding to P2Y12 receptor. This binding diminishes
the release of alpha and dense granules from platelets (Garcia et al, 2011) and also inhibits
beta3 integrin engagement, attenuating the synthesis of IL-1beta induced upon platelet
stimulation (Lindemann et al, 2001; Su et al, 2012). In the majority of studies Clopidogrel
inhibits expression of inflammatory markers and reduces leukocyte activation (Ayral et al,
2007; Evangelista et al, 2005). Moreover, clopidogrel inhibits the progression of
atherosclerotic lesions by reducing levels of inflammatory factors (Li et al, 2007). On the
other hand, in a rat experimental arthritis model, treatment with clopidogrel had a pro-
inflammatory effect measured by clinical manifestations of inflammation, elevated
neutrophil blood count and the plasma levels of pro-inflammatory cytokines (Garcia et al,
2011). Aspirin inhibits the activity of cyclooxygenases and promotes the expression of
lipoxins and resolvins (Chiang & Serhan, 2006). In addition to inhibiting platelets aspirin
works through a number of different pathways that can reduce inflammation (Dovizio et al,
2013; Berk et al, 2013). Aspirin has also been shown to reduce PMN infiltration related to
inflammation (Gil-Villa et al, 2012).
We have used a well-established model of experimental periodontal disease that presents
histological and immunological characteristics similar to those of periodontal disease in
humans (Holzhausen, 2005; Guimarães, 2007; Nassar, 2009; Spolidorio, 2010). The removal
of the pathogenic stimulus represented by the ligatures may be considered similar to
periodontal disease treatment by the removal of dental biofilm and calculus, allowing the
evaluation of the repair process. In the periodontal repair process established 3 days after the
removal of the stimulus, it is expected to see a slightly decrease in the inflammatory process
characterized by a decrease in polymorphonuclear leucocytes migration to the site of injury.
It is possible that a platelet-derived CXCL4 and CCL5 signaling mechanism is involved in
this recruitment. In fact, CXCL4 is a potent inhibitor of angiogenesis and, together with
CCL5, participates in the recruitment of polymorphonuclear leukocytes and monocytes into
the blood vessel wall (Flad & Brandt, 2010). Our results indicate that both clopidogrel and
aspirin reduced production of chemokines CXCL4 and CCL5; this result was somewhat
unexpected given the prominent role of CCL5 in the inflammatory process supported by the
literature. Offenbacher (2009) and Thunell (2010) showed high levels of CCL5 in
periodontal disease in humans. Also, Gamonal (2000) demonstrated a marked CCL5
reduction in gingival crevicular fluid, after periodontal treatment in humans. The differences
in the main source of both chemokines can partially explain our results. While platelets are
not the main source of CCL5 (it can also be produced by other cell types in the gingival
tissues, such as epithelial cells, fibroblasts and macrophages), CXCL4 is only released from
alpha-granules of activated platelets. Our research group has previously reported an anti-
inflammatory effect associated with systemic administration of aspirin and clopidogrel in a
rat ligature-induced periodontal disease model, which was characterized by a reduction in
the influx of inflammatory cells and consistent decrease in the production of
proinflammatory cytokines (IL-6, TNF-alpha and TXA-2), even thought it did not affect
periodontal repair, 15 days after the removal of the pathogenic stimulus (Coimbra, 2011). In
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the present study we have used a 3-day experimental time point. The major point to be
considered regarding the differences in the results observed would be that growth factors
and other biological mediators secreted by platelets with a prominent role in the repair
process have a major importance in the beginning of the pathophysiology of the repair
process
There was a marked reduction in osteoclast numbers in the tissues of clopidogrel-treated
animals, which may be a direct effect of this drug on osteoclastogenesis or an indirect effect
related with the modulation of the cytokine network and the pro- and anti-osteoclastic
factors. P2RY2 receptors, which are inhibited by clopidogrel play a role in pathologic bone
loss induced by arthritis, tumor growth in bone in osteoporosis (Su et al, 2012). In addition
ADP, which is the natural ligand for P2RY2 receptors can stimulate osteoclast formation in
vitro (Hoebertz et al, 2001). Gruber et al (2003) showed that treatment with aspirin had no
effect in osteoclastogenesis, suggesting that the anti-inflammatory effects of aspirin are not
related to this mechanism.
According to our results, clopidogrel but not aspirin enhanced angiogenesis by increasing
the number of blood vessels and reducing PDGF expression during periodontal repair.
Interestingly, Clop has been shown to affect platelet degranulation, reducing secretion of
PDGF, which plays an important role on tissue repair and angiogenesis (Graff et al, 2002).
Regarding the angiogenic process we can partially explain the link between the increase in
the number of blood vessels and PDGF expression as platelets are a primary source of this
growth factor. Moreover, Duelsner et al (2012) showed that aspirin, but not clopidogrel,
inhibits arteriogenesis in vivo and in vitro. Another point to be raised is that this result can
be due to a sampling error. Because Clop-treated animals had a reduced inflammation and
thus less tissue volume, consequently had an increase in vessel density, rather than a true
increase in the number of vessels.
In summary, we showed that after removal of the pathologic stimulus in the early/transition
phase between disease-associated inflammation and repair both aspirin and clopidogrel
decrease the production of chemokines associated with leukocyte chemotaxis in the
periodontal microenvironment. Overall, the effects of clopidogrel were more potent than
those of aspirin. Thus, clopidogrel had a stronger effect in reducing PMN infiltration,
attachment and bone loss and osteoclast number and increasing bone percentage and blood
vessels suggesting that it may have therapeutic value under situations where tissues undergo
a transition from inflammation to repair.
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CLINICAL RELEVANCE
Scientific rationale
Systemic administration of antiplatelet drugs might interfere with periodontal repair by
suppressing the release of biological mediators.
Principal findings
Clopidogrel, but not aspirin, appears to have improved the repair process showed by an
increase in blood vessels number, reduced leukocyte count, augmented bone percentage
and significant reduction in the attachment loss and CEJ-ABC distance.
Practical implications
Aspirin and Clopidogrel, the two most frequently prescribed antiplatelet drugs in patients
with cardiovascular diseases may affect the inflammatory and repair process in
periodontal disease.
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FIGURE 1.
Effect of systemic treatment with Asp or Clop on the gingival contents of CCL5 (panel A),
CXCL4 (panel B), CXCL12 (panel C) in rats with ligature induced periodontal disease when
stimulus is removed. Results were normalized to the total protein contents in each sample
and expressed as pg/mg of protein. Values are expressed as mean±SD. * P<0.0001 vs Repair
(Rep)+ NaCl, Rep+ Asp, Rep+ Clop; **P<0.001 vs Clop; #P<0.0001 vs Rep+ Asp, Rep+
Clop; ##P<0.001 vs Rep+ Asp and Rep+ Clop.
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FIGURE 2.
Effect of systemic treatment with Asp or Clop on the gingival contents of PDGF in rats with
ligature induced periodontal disease when stimulus is removed. Results were normalized to
the total protein contents in each sample and expressed as pg/mg of protein. Values are
expressed as mean±SD. *P<0.001 vs Rep+ Clop.
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FIGURE 3.
Histological analysis of the alveolar bone crest/gingival margin region of right lower first
molar stained with hematoxylin and eosin (H&E). Images are representative of the results
observed in 5 animals in each group. 200X magnification.
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FIGURE 4.
Effect of systemic treatment with Asp or Clop on the PMN count (panel A); attachment loss
(panel B); alveolar bone loss (panel C) and bone percentage (panel D) in animals submitted
or not to experimental periodontal disease. The results are representative from 5 animals/
group. Values are expressed as mean±SD. *P<0.0001 vs Rep+Clop; #P<0.001 vs Rep+Clop.
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FIGURE 5.
Immunohistochemistry sections of the alveolar bone crest of right lower first molar of rats
stained with anti-tartrate-resistant acid phosphatase (TRAP) to measure osteoclast number.
Images are representative of the results observed in 5 animals in each group. 200X
magnification.
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FIGURE 6.
Effect of systemic treatment with Asp or Clop on the osteoclast number in rats with ligature
induced periodontal disease when stimulus is removed. Values are expressed as mean±SD.
*P<0.0001 vs Clop, Rep+Clop.
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FIGURE 7.
Effect of systemic treatment with Asp or Clop on the number of blood vessels in rats
submitted or not to experimental periodontal repair. The results are representative from 5
animals/group. Values are expressed as mean±SD. *P<0.0001 vs Rep+Clop.
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